ReviewSeminars in radiation oncology2015
Radiation Therapy Oncology Group 9802: Controversy or Consensus in the Treatment of Newly Diagnosed Low-Grade Glioma?
Review in Seminars in radiation oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas.Neuro-oncology · 2024Pooled it
- Early versus delayed postoperative radiotherapy for treatment of low-grade gliomas.The Cochrane database of systematic reviews · 2020Pooled it
- Estimating temporal treatment-effect patterns of radiotherapy and chemotherapy in lower-grade gliomas using causal machine learning.Scientific reports · 2026Article
- Unravelling differences and hallmarks in suspected diffuse low-grade gliomas: a multicentre database study.Brain communications · 2025Article
- Multidisciplinary Management of Isocitrate Dehydrogenase-Mutated Gliomas in a Contemporary Molecularly Defined Era.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Review
- Dosimetry comparison with helical tomotherapy, volumetric modulated arc therapy, and intensity-modulated radiotherapy for grade II gliomas: A single‑institution case series.Open life sciences · 2023Article
- Glioma targeted therapy: insight into future of molecular approaches.Molecular cancer · 2022Review
- Considerations for a surgical RCT for diffuse low-grade glioma: a survey.Neuro-oncology practice · 2020Article
- Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network.Neuro-oncology practice · 2019Article
- Relationship of In Vivo MR Parameters to Histopathological and Molecular Characteristics of Newly Diagnosed, Nonenhancing Lower-Grade Gliomas.Translational oncology · 2018Article
- Survey on current practice within the European Low-Grade Glioma Network: where do we stand and what is the next step?Neuro-oncology practice · 2017Article
- Efficacy and prognosis of surgery combined withOncology letters · 2017Article
- [Critical consideration of the European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas].Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2017Article
- Management of supratentorial recurrent low-grade glioma: A multidisciplinary experience in 35 adult patients.Oncology letters · 2017Article
- [Epilepsy-associated tumors of the central nervous system: Epilepsy surgery and oncological aspects].Der Nervenarzt · 2016Review
- Current Management of Adult Diffuse Infiltrative Low Grade Gliomas.Current neurology and neuroscience reports · 2016Article
- Hemizygous deletion ofNeuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Treatment of newly diagnosed or suspected low-grade glioma (LGG) is one of the most controversial areas in neuro-oncology. The heterogeneity of these tumors, concern regarding morbidity of treatment, and absence of proven overall survival benefit from any known treatment have resulted in a lack of consensus regarding the timing and extent of surgery, timing of radiotherapy (RT), and role of chemotherapy. The long-term results of Radiation Therapy Oncology Group (RTOG) 9802, a phase III randomized trial comparing RT alone with RT and 6 cycles of adjuvant procarbazine, CCNU, vincristine (PCV), demonstrated an unprecedented 5.5-year improvement in median overall survival with the addition of PCV chemotherapy in high-risk patients with LGG. These results are practice changing and define a new standard of care for these patients. However, in the intervening decade since the trial was completed, novel molecular markers as well as newer chemotherapy agents such as temozolomide have been developed, which make these results difficult to incorporate into clinical practice. This review summarizes the evidence for and against the role of upfront RT and PCV in newly diagnosed patients with LGG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.